The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has authorized Sanofi’s (Euronext: SAN) SARS-CoV-2 spike protein (B.1.351 strain) vaccine for the prevention of COVID-19 disease in adults in Great Britain.
This follows on from the European Commission approval that was granted last month, which included Northern Ireland.
The approval is as a booster for active immunization to prevent COVID-19 in adults who have previously received an mRNA or adenoviral COVID-19 vaccine.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze